Skip to content
Bored Studies
RecruitingPhase 2

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

Yarrow Bioscience, Inc. · NCT07682896

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
232
US sites recruiting
22
Study start
June 10, 2026
Record last updated
October 5, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.

The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2.

Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.

Being studied: Experimental: YB-101; Placebo YB-101

Conditions: Graves' Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment
  • Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening
  • Additional inclusion criteria are defined in the protocol

Exclusion Criteria

  • Previously treated with radioactive iodine (RAI) therapy or underwent total thyroidectomy
  • Received any dose of levothyroxine, desiccated thyroid extract, or T3 within 6 weeks before screening
  • Current treatment with teprotumumab or exposure to teprotumumab within 15 weeks prior to screening
  • History of hyperthyroidism not caused by Graves' disease (eg. toxic adenoma, or toxic multinodular goiter) within 6 months before the screening visit
  • Pregnant or lactating women
  • Additional exclusion criteria are defined in the protocol

Recruiting US locations

Study contacts (from the official record)

  • Victoria Lacasse, MD · 469-278-6161 · VL@YarrowBioscience.com
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics,… (NCT07682896) | Bored Studies